- Home
- DXR vs MYO Comparison
DXR vs MYO Comparison
Compare DXR & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- MYO
- Stock Information
- Founded
- DXR 1970
- MYO 2004
- Country
- DXR United States
- MYO United States
- Employees
- DXR N/A
- MYO N/A
- Industry
- DXR Medical/Dental Instruments
- MYO Industrial Specialties
- Sector
- DXR Health Care
- MYO Health Care
- Exchange
- DXR Nasdaq
- MYO Nasdaq
- Market Cap
- DXR 46.9M
- MYO 44.6M
- IPO Year
- DXR N/A
- MYO 2017
- Fundamental
- Price
- DXR $11.20
- MYO $0.99
- Analyst Decision
- DXR Strong Buy
- MYO Strong Buy
- Analyst Count
- DXR 1
- MYO 3
- Target Price
- DXR $25.00
- MYO $8.17
- AVG Volume (30 Days)
- DXR 10.4K
- MYO 2.1M
- Earning Date
- DXR 01-01-0001
- MYO 11-05-2025
- Dividend Yield
- DXR N/A
- MYO N/A
- EPS Growth
- DXR 3.46
- MYO N/A
- EPS
- DXR 0.36
- MYO N/A
- Revenue
- DXR $66,306.00
- MYO $40,760,091.00
- Revenue This Year
- DXR N/A
- MYO $25.69
- Revenue Next Year
- DXR N/A
- MYO $23.52
- P/E Ratio
- DXR $30.67
- MYO N/A
- Revenue Growth
- DXR N/A
- MYO 93.08
- 52 Week Low
- DXR $6.55
- MYO $0.92
- 52 Week High
- DXR $11.48
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- DXR 57.09
- MYO 25.53
- Support Level
- DXR $10.27
- MYO $0.96
- Resistance Level
- DXR $11.48
- MYO $1.17
- Average True Range (ATR)
- DXR 0.54
- MYO 0.08
- MACD
- DXR -0.02
- MYO 0.03
- Stochastic Oscillator
- DXR 81.08
- MYO 10.92
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).